Cargando…
Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicin...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592392/ https://www.ncbi.nlm.nih.gov/pubmed/31199346 http://dx.doi.org/10.2196/12377 |
_version_ | 1783429880202919936 |
---|---|
author | Farmer, Andrew Bobrow, Kirsty Leon, Natalie Williams, Nicola Phiri, Enita Namadingo, Hazel Cooper, Sara Prince, John Crampin, Amelia Besada, Donela Daviaud, Emmanuelle Yu, Ly-Mee Ngoma, Jonathan Springer, David Pauly, Bruno Norris, Shane Tarassenko, Lionel Nyirenda, Moffat Levitt, Naomi |
author_facet | Farmer, Andrew Bobrow, Kirsty Leon, Natalie Williams, Nicola Phiri, Enita Namadingo, Hazel Cooper, Sara Prince, John Crampin, Amelia Besada, Donela Daviaud, Emmanuelle Yu, Ly-Mee Ngoma, Jonathan Springer, David Pauly, Bruno Norris, Shane Tarassenko, Lionel Nyirenda, Moffat Levitt, Naomi |
author_sort | Farmer, Andrew |
collection | PubMed |
description | BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited. OBJECTIVE: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control. METHODS: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A(1c) (HbA(1c)) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the collection of medication and assess the reception of the intervention by participants and health care workers. RESULTS: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation. CONCLUSIONS: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied. TRIAL REGISTRATION: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk) INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12377 |
format | Online Article Text |
id | pubmed-6592392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65923922019-07-17 Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial Farmer, Andrew Bobrow, Kirsty Leon, Natalie Williams, Nicola Phiri, Enita Namadingo, Hazel Cooper, Sara Prince, John Crampin, Amelia Besada, Donela Daviaud, Emmanuelle Yu, Ly-Mee Ngoma, Jonathan Springer, David Pauly, Bruno Norris, Shane Tarassenko, Lionel Nyirenda, Moffat Levitt, Naomi JMIR Res Protoc Protocol BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited. OBJECTIVE: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control. METHODS: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A(1c) (HbA(1c)) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the collection of medication and assess the reception of the intervention by participants and health care workers. RESULTS: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation. CONCLUSIONS: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied. TRIAL REGISTRATION: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk) INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12377 JMIR Publications 2019-05-30 /pmc/articles/PMC6592392/ /pubmed/31199346 http://dx.doi.org/10.2196/12377 Text en ©Andrew Farmer, Kirsty Bobrow, Natalie Leon, Nicola Williams, Enita Phiri, Hazel Namadingo, Sara Cooper, John Prince, Amelia Crampin, Donela Besada, Emmanuelle Daviaud, Ly-Mee Yu, Jonathan Ngoma, David Springer, Bruno Pauly, Shane Norris, Lionel Tarassenko, Moffat Nyirenda, Naomi Levitt. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.05.2019. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included. |
spellingShingle | Protocol Farmer, Andrew Bobrow, Kirsty Leon, Natalie Williams, Nicola Phiri, Enita Namadingo, Hazel Cooper, Sara Prince, John Crampin, Amelia Besada, Donela Daviaud, Emmanuelle Yu, Ly-Mee Ngoma, Jonathan Springer, David Pauly, Bruno Norris, Shane Tarassenko, Lionel Nyirenda, Moffat Levitt, Naomi Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title | Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title_full | Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title_fullStr | Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title_full_unstemmed | Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title_short | Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial |
title_sort | mobile messaging support versus usual care for people with type 2 diabetes on glycemic control: protocol for a multicenter randomized controlled trial |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592392/ https://www.ncbi.nlm.nih.gov/pubmed/31199346 http://dx.doi.org/10.2196/12377 |
work_keys_str_mv | AT farmerandrew mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT bobrowkirsty mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT leonnatalie mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT williamsnicola mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT phirienita mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT namadingohazel mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT coopersara mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT princejohn mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT crampinamelia mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT besadadonela mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT daviaudemmanuelle mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT yulymee mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT ngomajonathan mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT springerdavid mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT paulybruno mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT norrisshane mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT tarassenkolionel mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT nyirendamoffat mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial AT levittnaomi mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial |